BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Epigenomics AG Reports Positive Results in Clinical Study for Epi ProColon 2.0.


9/19/2011 8:09:57 AM

(RTTNews) - Epigenomics AG (ECX.DE,EPGNF.PK: News ) Monday reported positive results in a clinical study for the company's second generation blood-based test for the early detection of colorectal cancer, Epi proColon 2.0. In the study, 98 patients with colorectal cancer and 149 patients with no evidence of disease as verified by colonoscopy were tested with the Epi proColon 2.0 test. The test identified 95% of the cancer cases at a specificity of 85%. The new study provides the clinical evidence required for CE-marking of Epi proColon 2.0 for launch in the European market later this year. The study is expected to be initiated and completed in time for a submission to FDA before year-end 2011.

Read at RTT News

RTT News
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES